The Costs and the Consequences of Determining Venue Post-Valeant v. Mylan: Coordinating Multiple ANDA Suits through MDLs

April 26, 2022 1:45pm

David L. Anstaett
Perkins Coie LLP

Steven Maslowski
Akin Gump Strauss Hauer & Feld LLP

Mark Rubinshtein, Ph.D.
Knobbe Martens

Moderated by:

Jeanna M. Wacker
Kirkland & Ellis LLP

  • Reviewing the Federal Circuit’s holding in Celgene v. Mylan from November 2021 where Celgene’s argument that a branded drug company should be able to file suit where it receives notice was rejected
  • Anticipating circumstances when brands can file suit where generics reside toward using multidistrict litigation for the consolidation of discovery
    • Coordinating MDLs “to promote the just and efficient conduct of the patent infringement actions”
  • Identifying when parties may agree to proceed in one jurisdiction to streamline litigation
  • Reconciling when Maryland (where U.S. FDA is located) may be a proper venue for Hatch-Waxman litigation